{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:02Z","timestamp":1790351462960,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71375-2","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:00:02Z","timestamp":1775534402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ponatinib inhibits LCK and PI3K signaling and promotes CD8+ T stem cell memory cell development"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5253-5370","authenticated-orcid":false,"given":"Yuki","family":"Okuhiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-7089","authenticated-orcid":false,"given":"Sachiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2549","authenticated-orcid":false,"given":"Keisuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7553-167X","authenticated-orcid":false,"given":"Takahiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-7462","authenticated-orcid":false,"given":"Yuki","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6563-9807","authenticated-orcid":false,"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"71375_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"71375_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+ PD-1+ CD8+ T Cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211 (2019).","journal-title":"Immunity"},{"key":"71375_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u2212 CD8+ tumor-infiltrating T cells. Immunity 50, 181\u2013194 (2019).","journal-title":"Immunity"},{"key":"71375_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli, S. et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Invest. 132, e150807 (2022).","journal-title":"J. Clin. Invest."},{"key":"71375_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","volume":"8","author":"Z Bai","year":"2022","unstructured":"Bai, Z. et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci. Adv. 8, eabj2820 (2022).","journal-title":"Sci. Adv."},{"key":"71375_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401\u2013412 (2009).","journal-title":"Cancer Cell"},{"key":"71375_CR7","unstructured":"Food and Drug Administration. FDA approves ponatinib (Iclusig) for treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. U.S. Food and Drug Administration https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ponatinib (2012)."},{"key":"71375_CR8","unstructured":"Food and Drug Administration. FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. U.S. Food and Drug Administration https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome (2023)."},{"key":"71375_CR9","doi-asserted-by":"publisher","first-page":"e92146","DOI":"10.1371\/journal.pone.0092146","volume":"9","author":"JC Uitdehaag","year":"2014","unstructured":"Uitdehaag, J. C. et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE 9, e92146 (2014).","journal-title":"PLoS ONE"},{"key":"71375_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/cancers10110430","volume":"10","author":"F Musumeci","year":"2018","unstructured":"Musumeci, F., Greco, C., Grossi, G., Molinari, A. & Schenone, S. Recent studies on ponatinib in cancers other than chronic myeloid leukemia. Cancers 10, 430 (2018).","journal-title":"Cancers"},{"key":"71375_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit, J. M. et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 10, 1028\u20131035 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"71375_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit, J. M. et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11, 690\u2013699 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"71375_CR13","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1002\/cam4.2505","volume":"8","author":"EQ Lee","year":"2019","unstructured":"Lee, E. Q. et al. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 8, 5988\u20135994 (2019).","journal-title":"Cancer Med."},{"key":"71375_CR14","volume":"1","author":"JF Gainor","year":"2020","unstructured":"Gainor, J. F. et al. A phase II study of the multikinase inhibitor ponatinib in patients with advanced, RET-rearranged NSCLC. JTO Clin. Res. Rep. 1, 100045 (2020).","journal-title":"JTO Clin. Res. Rep."},{"key":"71375_CR15","volume":"3","author":"KC Arbour","year":"2022","unstructured":"Arbour, K. C. et al. Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations. JTO Clin. Res. Rep. 3, 100256 (2022).","journal-title":"JTO Clin. Res. Rep."},{"key":"71375_CR16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.20517\/cdr.2023.89","volume":"6","author":"PL Sweeney","year":"2023","unstructured":"Sweeney, P. L., Suri, Y., Basu, A., Koshkin, V. S. & Desai, A. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer Drug Resist. 6, 858\u2013873 (2023).","journal-title":"Cancer Drug Resist."},{"key":"71375_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro, A., J\u00e4nne, P. A., Mok, T. & Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2, 377\u2013391 (2021).","journal-title":"Nat. Cancer"},{"key":"71375_CR18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191009","volume":"217","author":"A Tanaka","year":"2020","unstructured":"Tanaka, A. et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J. Exp. Med. 217, e20191009 (2020).","journal-title":"J. Exp. Med."},{"key":"71375_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes, J. E. et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 369, 1783\u20131796 (2013).","journal-title":"N. Engl. J. Med."},{"key":"71375_CR20","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson, R. A. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022\u20134028 (2008).","journal-title":"Blood"},{"key":"71375_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"71375_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abk0957","volume":"7","author":"K Itahashi","year":"2022","unstructured":"Itahashi, K. et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci. Immunol. 7, eabk0957 (2022).","journal-title":"Sci. Immunol."},{"key":"71375_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"71375_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"71375_CR25","first-page":"594","volume":"123","author":"E Lugli","year":"2013","unstructured":"Lugli, E. et al. Superior T memory stem cell persistence supports long-lived T cell memory. J. Clin. Invest. 123, 594\u2013599 (2013).","journal-title":"J. Clin. Invest."},{"key":"71375_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808\u2013813 (2009).","journal-title":"Nat. Med."},{"key":"71375_CR27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1326","volume":"11","author":"Y Zhang","year":"2005","unstructured":"Zhang, Y., Joe, G., Hexner, E., Zhu, J. & Emerson, S. G. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat. Med. 11, 1299\u20131305 (2005).","journal-title":"Nat. Med"},{"key":"71375_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma, V. et al. MEK inhibition reprograms CD8\u207a T lymphocytes into memory stem cells with potent antitumor effects. Nat. Immunol. 22, 53\u201366 (2021).","journal-title":"Nat. Immunol."},{"key":"71375_CR29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"71375_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell ehaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"71375_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ni1428","volume":"8","author":"JM Kim","year":"2007","unstructured":"Kim, J. M., Rasmussen, J. P. & Rudensky, A. Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191\u2013197 (2007).","journal-title":"Nat. Immunol."},{"key":"71375_CR32","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"71375_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41577-021-00537-8","volume":"21","author":"M Reina-Campos","year":"2021","unstructured":"Reina-Campos, M., Scharping, N. E. & Goldrath, A. W. CD8+ T cell metabolism in infection and cancer. Nat. Rev. Immunol. 21, 718\u2013738 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"71375_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4161\/self.1.3.12968","volume":"1","author":"P Riha","year":"2010","unstructured":"Riha, P. & Rudd, C. E. CD28 co-signaling in the adaptive immune response. Self Nonself 1, 231\u2013240 (2010).","journal-title":"Self Nonself"},{"key":"71375_CR35","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.4049\/jimmunol.181.5.2980","volume":"181","author":"S Fabre","year":"2008","unstructured":"Fabre, S. et al. FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J. Immunol. 181, 2980\u20132989 (2008).","journal-title":"J. Immunol."},{"key":"71375_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"71375_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"71375_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1034\/j.1600-065X.2003.00015.x","volume":"191","author":"R Zamoyska","year":"2003","unstructured":"Zamoyska, R. et al. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol. Rev. 191, 107\u2013118 (2003).","journal-title":"Immunol. Rev."},{"key":"71375_CR39","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/384484a0","volume":"384","author":"H Yamaguchi","year":"1996","unstructured":"Yamaguchi, H. & Hendrickson, W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384, 484\u2013489 (1996).","journal-title":"Nature"},{"key":"71375_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"71375_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).","journal-title":"Science"},{"key":"71375_CR42","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005).","journal-title":"J. Clin. Invest."},{"key":"71375_CR43","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"71375_CR44","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng, B. et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature 634, 712\u2013720 (2024).","journal-title":"Nature"},{"key":"71375_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"71375_CR46","unstructured":"Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review(s): SPRYCEL (dasatinib). U.S. Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021986s000_Sprycel__ClinPharmR.pdf (2006)."},{"key":"71375_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk3160","volume":"17","author":"H Nishinakamura","year":"2025","unstructured":"Nishinakamura, H. et al. Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade. Sci. Transl. Med. 17, eadk3160 (2025).","journal-title":"Sci. Transl. Med."},{"key":"71375_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-017-0238-1","volume":"5","author":"MJ Reilley","year":"2017","unstructured":"Reilley, M. J. et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J. Immunother. Cancer 5, 35 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"71375_CR49","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1158\/1078-0432.CCR-16-2349","volume":"23","author":"SP D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo, S. P. et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab. Clin. Cancer Res. 23, 2972\u20132980 (2017).","journal-title":"Clin. Cancer Res."},{"key":"71375_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-024-08194-2","volume":"637","author":"M Wagner","year":"2025","unstructured":"Wagner, M., Nishikawa, H. & Koyasu, S. Reinventing type 2 immunity in cancer. Nature 637, 296\u2013303 (2025).","journal-title":"Nature"},{"key":"71375_CR51","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","volume":"316","author":"AP Singh","year":"2020","unstructured":"Singh, A. P. et al. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib. Int. J. Cardiol. 316, 214\u2013221 (2020).","journal-title":"Int. J. Cardiol."},{"key":"71375_CR52","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes, J. et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138, 2042\u20132050 (2021).","journal-title":"Blood"},{"key":"71375_CR53","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/eurheartj\/ehaa959","volume":"42","author":"M Totzeck","year":"2021","unstructured":"Totzeck, M., Stuschke, M. & Schuler, M. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur. Heart J. 42, 2043\u20132051 (2021).","journal-title":"Eur. Heart J."},{"key":"71375_CR54","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"71375_CR55","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","volume":"108","author":"S Mumprecht","year":"2006","unstructured":"Mumprecht, S., Matter, M., Pavelic, V. & Ochsenbein, A. F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108, 3406\u20133413 (2006).","journal-title":"Blood"},{"key":"71375_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101557","volume":"3","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi, T. et al. Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. STAR Protoc. 3, 101557 (2022).","journal-title":"STAR Protoc."},{"key":"71375_CR57","doi-asserted-by":"publisher","first-page":"W3","DOI":"10.1093\/nar\/gkw343","volume":"44","author":"E Afgan","year":"2016","unstructured":"Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 44, W3\u2013W10 (2016).","journal-title":"Nucleic Acids Res."},{"key":"71375_CR58","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"71375_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"71375_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"71375_CR61","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71375_CR62","first-page":"3.16B.11","volume":"113","author":"GJW van der Windt","year":"2016","unstructured":"van der Windt, G. J. W., Chang, C. H. & Pearce, E. L. Measuring bioenergetics in T cells using a seahorse extracellular flux analyzer. Curr. Protoc. Immunol. 113, 3.16B.11\u201313.16B.14 (2016).","journal-title":"Curr. Protoc. Immunol."},{"key":"71375_CR63","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"71375_CR64","doi-asserted-by":"publisher","first-page":"14950","DOI":"10.1073\/pnas.95.25.14950","volume":"95","author":"M Aoki","year":"1998","unstructured":"Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P. & Vogt, P. K. The Akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA 95, 14950\u201314955 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71375_CR65","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"71375_CR66","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453\u20131464 (2009).","journal-title":"Mol. Ther."},{"key":"71375_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).","journal-title":"Genome Biol."},{"key":"71375_CR68","doi-asserted-by":"publisher","first-page":"vbac016","DOI":"10.1093\/bioadv\/vbac016","volume":"2","author":"P Badia-I-Mompel","year":"2022","unstructured":"Badia-I-Mompel, P. et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinform. Adv. 2, vbac016 (2022).","journal-title":"Bioinform. Adv."},{"key":"71375_CR69","doi-asserted-by":"publisher","first-page":"btad547","DOI":"10.1093\/bioinformatics\/btad547","volume":"39","author":"B Muzellec","year":"2023","unstructured":"Muzellec, B., Tele\u0144czuk, M., Cabeli, V. & Andreux, M. PyDESeq2: a python package for bulk RNA-seq differential expression analysis. Bioinformatics 39, btad547 (2023).","journal-title":"Bioinformatics"},{"key":"71375_CR70","doi-asserted-by":"publisher","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 (2023).","journal-title":"Bioinformatics"},{"key":"71375_CR71","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes, J. E. et al. Ponatinib in refractory Philadelphia chromosome\u2013positive leukemias. N. Engl. J. Med. 369, 1783\u20131796 (2013).","journal-title":"N. Engl. J. Med."},{"key":"71375_CR72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/jcph.1990","volume":"62","author":"MJ Hanley","year":"2022","unstructured":"Hanley, M. J. et al. Population pharmacokinetics of ponatinib in healthy adult volunteers and patients with hematologic malignancies and model-informed dose selection for pediatric development. J. Clin. Pharmacol. 62, 555\u2013567 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"71375_CR73","first-page":"85","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2013response analysis of a Phase III study. Clin. Pharmacology: Adv. Appl. 5, 85\u201397 (2013).","journal-title":"Clin. Pharmacology: Adv. Appl."},{"key":"71375_CR74","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","volume":"62","author":"MBA van der Kleij","year":"2023","unstructured":"van der Kleij, M. B. A. et al. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clin. Pharmacokinet. 62, 1333\u20131364 (2023).","journal-title":"Clin. Pharmacokinet."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71375-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:03:50Z","timestamp":1780531430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71375-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71375"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71375-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.N. received research funding and honoraria (lecture fee) from Ono Pharmaceutical, BMS, Chugai Pharmaceutical, BD Japan, Eisai and MSD; received honoraria (lecture fee) from Amgen; received research funding from Taiho Pharmaceutical, Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debiopharma, Rakuten Medical, Gliead-Kite Pharma, Moderna, Asahi-Kasei, Sysmex, Fujifilm, SRL, Hitachi, Astellas Pharmaceutical, Sumitomo Pharma, ARC Therapies, Meiji Seika Pharma, MiraBiologics, and RIKAKEN Holdings; and served as a founder and a scientific advisor of ARC Therapies and a scientific advisor of LTZ Therapeutics outside of this study. Y.M. and K.W. are founders and directors of ARC Therapies outside of this study. H.K. received research funding from FUJIFILM, Kyowa-Kirin, Bristol-Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, Abbvie, CURED, Astellas Pharma, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, and Sanofi, and honoraria from Abbvie, Chugai, Astellas Pharma, and Novartis. N.T. received research funding from Asahi-Kasei Pharma Corporation, Otsuka Pharmaceutical, Novartis, and Pfizer. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4934"}}